Attenuation of microRNA-22 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy

Journal of Cellular Physiology

Volumn 227, Issue 4, 2012, Pages 1391-1398

  Xu, Xu Dong ^a   Song, Xiao Wei ^a   Li, Qing ^b   Wang, Guo Kun ^a,b   Jing, Qing ^a,b   Qin, Yong Wen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CELL MARKER; LUCIFERASE; MICRORNA; MICRORNA 22; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ALGORITHM; ANIMAL CELL; ARTICLE; CELL LEVEL; CELL SIZE; ENZYME ASSAY; GENE OVEREXPRESSION; HEART HYPERTROPHY; HEART MUSCLE CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; BASE SEQUENCE; CARDIOMEGALY; CELL ENLARGEMENT; CELLS, CULTURED; DNA PRIMERS; MICRORNAS; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; PHENYLEPHRINE; PTEN PHOSPHOHYDROLASE; RATS; UP-REGULATION;

RATTUS;

EID: 84862959239     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22852     Document Type: Article

References (56)

1. Ambros V. 2003. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell 113:673-676.
2. Araujo AS, Diniz GP, Seibel FE, Branchini G, Ribeiro MF, Brum IS, Khaper N, Barreto-Chaves ML, Bello-Klein A. 2011. Reactive oxygen and nitrogen species balance in the determination of thyroid hormones-induced cardiac hypertrophy mediated by renin-angiotensin system. Mol Cell Endocrinol 333:78-84.
3. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. 2005. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122:553-563.
4. Bar N, Dikstein R. 2010. miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PloS one 5:e10859.
5. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
6. Boriani G, Gasparini M, Landolina M, Lunati M, Biffi M, Santini M, Padeletti L, Molon G, Botto G, De Santo T, Valsecchi S. 2009. Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: Comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry. Eur Heart J 30:2275-2283.
7. Buller B, Liu X, Wang X, Zhang RL, Zhang L, Hozeska-Solgot A, Chopp M, Zhang ZG. 2010. MicroRNA-21 protects neurons from ischemic death. FEBS J 277:4299-4307.
8. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH, Wang DZ. 2009. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119:2772-2786.
9. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. 2007. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613-618.
10. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. 2006. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38:228-233.
11. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ. 2008. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 105:2111-2116.
12. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. 2007. MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a role in cardiac hypertrophy? Am J Pathol 170:1831-1840.
13. Chuzhanova N, Cooper DN, Ferec C, Chen JM. 2007. Searching for potential microRNA-binding site mutations amongst known disease-associated 3' UTR variants. Genomic Med 1:29-33.
14. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM. 2002. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110:737-749.
15. da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM, Molkentin JD, De Windt LJ. 2008. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118:1567-1576.
16. Divakaran V, Mann DL. 2008. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 103:1072-1083.
17. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. 2009. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104:170-178.
18. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP. 2005. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310:1817-1821.
19. Guo S, Lopez-Ilasaca M, Dzau VJ. 2005. Identification of calcium-modulating cyclophilin ligand (CAML) as transducer of angiotensin II-mediated nuclear factor of activated T cells (NFAT) activation. J Biol Chem 280:12536-12541.
20. Hu CM, Chen YH, Chiang MT, Chau LY. 2004. Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo. Circulation 110:309-316.
21. Huang J, Shelton JM, Richardson JA, Kamm KE, Stull JT. 2008. Myosin regulatory light chain phosphorylation attenuates cardiac hypertrophy. J Biol Chem 283:19748-19756.
22. Kass DA, Bronzwaer JG, Paulus WJ. 2004. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 94:1533-1542.
23. Kawashima T, Shioi T. 2010. MicroRNA, emerging role as a biomarker of heart failure. Circ J 75:268-269.
24. Kishimoto H, Hamada K, Saunders M, Backman S, Sasaki T, Nakano T, Mak TW, Suzuki A. 2003. Physiological functions of Pten in mouse tissues. Cell Struct Funct 28:11-21.
25. Kuster GM, Pimentel DR, Adachi T, Ido Y, Brenner DA, Cohen RA, Liao R, Siwik DA, Colucci WS. 2005. Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 111:1192-1198.
26. Langenickel TH, Buttgereit J, Pagel-Langenickel I, Lindner M, Monti J, Beuerlein K, Al-Saadi N, Plehm R, Popova E, Tank J, Dietz R, Willenbrock R, Bader M. 2006. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci USA 103:4735-4740.
27. Li HH, Willis MS, Lockyer P, Miller N, McDonough H, Glass DJ, Patterson C. 2007. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest 117:3211-3223.
28. Li Q, Song XW, Zou J, Wang GK, Kremneva E, Li XQ, Zhu N, Sun T, Lappalainen P, Yuan WJ, Qin YW, Jing Q. 2010. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci 123:2444-2452.
29. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. 2009. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci USA 106:12103-12108.
30. McManus DD, Chinali M, Saczynski JS, Gore JM, Yarzebski J, Spencer FA, Lessard D, Goldberg RJ. 2011. 30-year trends in heart failure in patients hospitalized with acute myocardial infarction. Am J Cardiol 107:353-359.
31. Oudit GY, Penninger JM. 2009. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82:250-260.
32. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. 2004. Fast and effective prediction of microRNA/target duplexes. RNA (New York, NY) 10:1507-1517.
33. Sakurai S, Ashida T, Ieki K, Takahashi N, Fujii J. 2003. Left ventricular regional variations in myosin isoform shift in Dahl salt-sensitive hypertensive rats. Hypertens Res 26:251-255.
34. Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj JU. 2010. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol 299:L861-871.
35. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. 2007. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100:416-424.
36. Schwartzbauer G, Robbins J. 2001. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem 276:35786-35793.
37. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. 2003. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199-208.
38. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. 2011. Antihypertensive treatment and development of heart failure in hypertension: A Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 171:384-394.
39. Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL, Walsh K. 2005. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 280:20814-20823.
40. Song XW, Li Q, Lin L, Wang XC, Li DF, Wang GK, Ren AJ, Wang YR, Qin YW, Yuan WJ, Jing Q. 2010. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol 225:437-443.
41. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ. 2007. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 42:1137-1141.
42. Thomson JM, Parker J, Perou CM, Hammond SM. 2004. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 1:47-53.
43. Trojnarska O. 2007. Heart failure in the adult patient with congenital heart disease. Cardiol J 14:127-136.
44. Van Herck PL, Vrints CJ, Carlier SG. 2005. Coronary circulation and interventional cardiology. Ann Biomed Eng 33:1735-1742.
45. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. 2006. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103:18255-18260.
46. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. 2007. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316:575-579.
47. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA. 2004. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24:8374-8385.
48. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q. 2010a. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659-666.
49. Wang K, Long B, Zhou J, Li PF. 2010b. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem 285:11903-11912.
50. Wen Y, Ma YX, Zhang XJ, Hong LF, Feng DY, Lu ZH. 2009. [Erythropoietin inhibits angiotensin II induced cardiomyocyte hypertrophy in vitro via activating PI3K/Akt-eNOS pathway]. Zhonghua xin xue guan bing za zhi [Chin J Cardiovasc Dis] 37:436-440.
51. Willis MS, Ike C, Li L, Wang DZ, Glass DJ, Patterson C. 2007. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 100:456-459.
52. Xia Y, Rajapurohitam V, Cook MA, Karmazyn M. 2004. Inhibition of phenylephrine induced hypertrophy in rat neonatal cardiomyocytes by the mitochondrial KATP channel opener diazoxide. J Mol Cell Cardiol 37:1063-1067.
53. Xu J, Hu Z, Xu Z, Gu H, Yi L, Cao H, Chen J, Tian T, Liang J, Lin Y, Qiu W, Ma H, Shen H, Chen Y. 2009. Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population. Hum Mutat 30:1231-1236.
54. Ye Y, Mou Y, Bai B, Li L, Chen GP, Hu SJ. 2010. Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy. Intern J Biochem Cell Biol 42:2056-2064.
55. Zafrir B, Paz H, Wolff R, Salman N, Merhavi D, Lewis BS, Amir O. 2010. Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. Eur J Intern Med 22:53-56.
56. Zhao Y, Samal E, Srivastava D. 2005. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436:214-220.